Blend is a biopharmaceutical company discovering new classes of medicines using a proprietary integrative approach to design superior drugs.
The defining feature of our approach is the synergistic application of two exclusive capabilities: our new-molecule drug discovery engine and our patented nanoparticle engineering platform.
Leveraging these assets, Blend discovers novel drugs with new modes of action and optimized therapeutic properties. Our initial focus is on cancer therapies that uniquely target tumors and improve potency and dose-limited toxicities, with reduced potential for resistance.
Our drug discovery engine has rapidly created a pipeline of differentiated new molecules, including:
- A new class of mono-functional platinum drugs
- Platinum NCEs within nanoparticles
- Other proprietary NCEs for oncology
- Combination therapy nanomedicines
Our team of scientists has deep industry experience in mechanism-driven drug design, nanoparticle engineering, and novel platinum drug discovery. Our world-class platinum drug discovery program is fueled by chemical insights provided by structural and innovative mechanistic studies.
Blend was founded by leaders in the fields of chemistry and nanomedicine, including Omid Farokzhad, MD, Associate Professor at Harvard Medical School and Brigham and Women’s Hospital and a nanomedicine expert; Robert Langer, Sc.D, Institute Professor at MIT and a nanomedicine expert; Stephen Lippard, PhD, Professor at MIT and a platinum chemistry expert.
Blend has attracted top-tier investors including Flagship Ventures, NanoDimension, and New Enterprise Associates.